FAQ on Oragenics Inc.'s Phase II Concussion Trial Submission in New Zealand
Summary
Oragenics Inc. has submitted a Phase II clinical trial protocol for its intranasal neurosteroid therapy, ONP-002, targeting mild traumatic brain injury (concussion) to New Zealand's Health and Disability Ethics Committee, aiming to start patient enrollment at Christchurch Hospital.
What is Oragenics Inc. submitting to New Zealand’s Health and Disability Ethics Committee?
Oragenics Inc. is submitting its Phase II clinical trial protocol for ONP-002, an intranasal neurosteroid therapy designed to treat mild traumatic brain injury (concussion).
Why is the submission of the Phase II clinical trial protocol significant?
This submission marks a critical step towards evaluating a potential treatment for concussion, addressing a major unmet medical need, and could lead to patient enrollment at Christchurch Hospital, expanding clinical reach in Australasia.
Where will the Phase II clinical trial take place if approved?
If approved, the trial will commence at Christchurch Hospital, one of the busiest emergency care centers in Australasia.
What is ONP-002?
ONP-002 is Oragenics Inc.’s intranasal neurosteroid therapy aimed at treating mild traumatic brain injury, also known as concussion.
How does Oragenics Inc. plan to expand its clinical reach?
The company aims to expand its clinical reach across Australia and New Zealand by initiating this Phase II trial, focusing on the treatment of concussion.
What other areas does Oragenics Inc. focus on besides concussion treatment?
Besides concussion treatment, Oragenics Inc. focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including treatments for Niemann Pick Disease Type C (NPC), and has proprietary powder formulation and an intranasal delivery device.
Where can I find more information about Oragenics Inc.?
More information about Oragenics Inc. can be found on their website at www.Oragenics.com or in the company’s newsroom at https://ibn.fm/OGEN.
What is the significance of the trial being conducted in New Zealand?
Conducting the trial in New Zealand, particularly at Christchurch Hospital, allows Oragenics Inc. to leverage one of Australasia’s busiest emergency care centers for patient enrollment, enhancing the trial’s efficiency and reach.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 121263